Compare ESPR & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | ORN |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 411.7M |
| IPO Year | 2013 | 2007 |
| Metric | ESPR | ORN |
|---|---|---|
| Price | $3.13 | $15.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $8.75 | ★ $16.25 |
| AVG Volume (30 Days) | ★ 16.8M | 320.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.71 | ★ 220.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | $403,135,000.00 | ★ $852,260,000.00 |
| Revenue This Year | N/A | $8.50 |
| Revenue Next Year | $12.81 | $7.83 |
| P/E Ratio | ★ N/A | $127.58 |
| Revenue Growth | ★ 21.31 | 7.01 |
| 52 Week Low | $0.76 | $6.44 |
| 52 Week High | $4.18 | $15.81 |
| Indicator | ESPR | ORN |
|---|---|---|
| Relative Strength Index (RSI) | 70.48 | 70.46 |
| Support Level | $2.37 | $10.01 |
| Resistance Level | $3.18 | $15.81 |
| Average True Range (ATR) | 0.06 | 0.85 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 95.65 | 96.26 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.